Author:
Hortobagyi G.N.,Stemmer S.M.,Burris H.A.,Yap Y.S.,Sonke G.S.,Paluch-Shimon S.,Campone M.,Petrakova K.,Blackwell K.L.,Winer E.P.,Janni W.,Verma S.,Conte P.,Arteaga C.L.,Cameron D.A.,Mondal S.,Su F.,Miller M.,Elmeliegy M.,Germa C.,O’Shaughnessy J.
Funder
Novartis Pharmaceuticals Corporation
Reference11 articles.
1. Ribociclib as first-line therapy for HR-positive, advanced breast cancer;Hortobagyi;N Engl J Med,2016
2. First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC);Hortobagyi;Ann Oncol,2016
3. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1);Eisenhauer;Eur J Cancer,2009
4. National Cancer Institute Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (1 June 2016, date last accessed).
5. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial;Sonke;Breast Cancer Res Treat,2018
Cited by
575 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献